South San Francisco, CA December 19, 2023 Press Release FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results If approved, Xolair would be the…
South San Francisco, CA October 11, 2023 Press Release Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based…
South San Francisco, CA October 4, 2023 Press Release Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment RAINBOWFISH study met its primary endpoint with 80% of…
South San Francisco, CA September 6, 2023 Press Release Acceptance based on the Phase III COMMODORE 2 study, which demonstrated crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal hemoglobinuria (PNH) If approved, crovalimab will be the first…
South San Francisco, CA September 2, 2023 Press Release ALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced setting About half…